Sophisticated solid dose formulations for fixed dose combinations – Jean-François Hilaire, Recipharm, explains how CDMOs can help optimise time-to-market
Michael Lehmann, executive vice president, global sales & marketing, Patheon shares his views on the challenges ahead for the pharma sector and how they could mean greater opportunities ahead for pharmaceutical manufacturers
2015 was a stellar year for Hovione. Roger Viney, senior business director, off patent API, outlines some of the key achievements leading to the company’s success
Colin White, general manager, Penn Pharma, A PCI company, PCI talks to EPM about the company’s recent expansions and its core business strengths going forward
The pharmaceutical manufacturers’ specialism in drug development, manufacturing and packaging services will complement PCI’s growth in clinical trial and commercial supply services in both North America and Europe.
In today’s dynamically changing environment, innovation and cost efficiency in drug development is crucial; costs of R&D are growing aggressively with an average investment of $1.3 billion required to successfully initiate a new drug to market...
Asia is the fastest growing pharmaceutical market in the world, providing significant opportunities for drug development and marketing. Consequently, pharmaceutical regulations in this region are fast gaining attention...
